RenovoRx Inc
RenovoRx, Inc., a clinical-stage biopharmaceutical company, engages in the developing of targeted combination therapies to enhance therapeutic outcomes for cancer patients undergoing treatment. Its lead product candidate is chemotherapy gemcitabine, which is provided through RenovoCath that is in Phase III clinical trials for the treatment of locally advanced pancreatic cancer. RenovoRx, Inc. was… Read more
RenovoRx Inc (RNXT) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.281x
Based on the latest financial reports, RenovoRx Inc (RNXT) has a cash flow conversion efficiency ratio of -0.281x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-2.27 Million) by net assets ($8.08 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
RenovoRx Inc - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how RenovoRx Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
RenovoRx Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of RenovoRx Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Zedge Inc
NYSE MKT:ZDGE
|
0.026x |
|
Volt Lithium Corp.
OTCQB:VLTLF
|
-0.436x |
|
Li Cheng Enterprise Co Ltd
TW:4426
|
-0.022x |
|
GAUMONT SA INH. EO 8
F:69N
|
N/A |
|
PGG Wrightson Limited
PINK:PGWFF
|
0.392x |
|
Enterprise Diversified Inc
OTCQB:ENDI
|
0.129x |
|
Hipages Group Holdings Ltd
AU:HPG
|
0.304x |
|
Denge Yatirim Holding AS
IS:DENGE
|
-0.066x |
Annual Cash Flow Conversion Efficiency for RenovoRx Inc (2019–2024)
The table below shows the annual cash flow conversion efficiency of RenovoRx Inc from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $4.48 Million | $-9.12 Million | -2.038x | -159.59% |
| 2023-12-31 | $-3.00 Million | $-10.26 Million | 3.419x | +339.17% |
| 2022-12-31 | $6.16 Million | $-8.81 Million | -1.430x | -270.92% |
| 2021-12-31 | $15.35 Million | $-5.92 Million | -0.385x | -260.12% |
| 2020-12-31 | $-14.66 Million | $-3.53 Million | 0.241x | +110.53% |
| 2019-12-31 | $1.47 Million | $-3.35 Million | -2.287x | -- |